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Abstract
New derivatives of natural compounds, galanthamine using in 
treatment of Alzheimer’s disease and antitumor dimer alkaloids 
vinblastine and vincristine were synthesized. In the course 
of the reaction between galanthamine and diazomethane in 
the presence of a catalyst, such as palladium(II) acetate or 
copper(I) bromide, methylene insertion into the aromatic ring 
was observed instead of the expected cyclopropanation of 
the carbon-carbon double bond. New vindoline derivatives 
conjugated with amino acid esters were prepared. In Simmons-
Smith reaction vinblastine and vincristine cyclopropanated 
in the carbon carbon double bond in position 14 and 15 of 
the vindoline monomer were obtained. New dimer alkaloids 
showed significant inhibiting effects in several tumor cell lines.
Keywords
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1 Introduction
Among the alkaloids and alkaloid-like compounds there 
are many biologically active derivatives with useful effects on 
some diseases. By structural modification of that compounds 
we can hopefully have even more useful derivatives. Several 
possibilities can be investigated. We tried the effect of intro-
duction of cyclopropane ring into some alkaloids or alkaloid-
like compounds.
2 Results and discussion
2.1 Galanthamine derivatives [1]
Galanthamine [2] (1) is a member of the Amaryllidaceae 
alkaloids, isolated from the Caucasian snowdrop (Galanthus 
woronowii) [3]. Galanthamine is a butyrylcholinesterase and 
acetylcholinesterase inhibitor [3,4] as well as an allosterically 
potentiating ligand of the neuronal nicotinic receptor, [5] cur-
rently used for the treatment of Alzheimer’s disease [5,6].
Many reports have described different synthetic routes to pre-
pare galanthamine [2,7-14], and with systematic transformations 
of its cyclic structure a number of derivatives were synthesized; 
e.g. by changing the position of the nitrogen atom in the azepine 
d ring [15], building in a sulfone group in ring d in place of the 
nitrogen atom [16], and substituting the furan b ring with pyrrole 
[17]. Derivatives without a furan b ring [18], compounds contain-
ing a nitrogen heteroatom in the aromatic ring a [19] and gal-
anthamine with an opened azepine d ring were also investigated 
[20]. The last result in the chemistry of galanthamine was the syn-
thesis of homogalanthamine (2) with a larger azepine ring [21].
A study of the literature data presented above led us to the 
concept of attempting to change the c ring by considering the 
carbon-carbon double bond as a target. The saturated deriva-
tive of galanthamine is known as lycoramine [3] and has a 
weaker biological effect, but the cyclopropano derivative (3) 
is unknown in the literature.
The cyclopropane subunit has always been considered as 
an electronically unique [22,23] structural element not only in 
the chemistry of artificial molecular structures [24] but in natu-
ral compounds as well [25-27]. Synthetic methods for the cy-
clopropanation of carbon-carbon double bond were reviewed 
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recently [28], the Simmons-Smith reaction [29,30], reaction 
with dimethyloxosulfonium methylide [31], and cyclopropana-
tion with diazomethane [32] in the presence of a catalyst are 
frequently used.
In our first approach to the cyclopropanation reaction of 
galanthamine (1) we used the Simmons-Smith method by al-
lowing 1 to react with diiodomethane [29] in the presence of 
diethylzinc at 0 oC or using trifluoroacetic acid [30] besides the 
aforementioned reagents at -15 oC. However, from these re-
actions only decomposition products were isolated. Secondly, 
a reaction between 1 and diazomethane - generated from N-
methyl-N-nitrosourea in dichloromethane solution in the pres-
ence of palladium(II) acetate [32] at 0 oC - resulted in a new 
derivative of galanthamine (Scheme 1). Cyclopropanation has 
not taken place but from the reaction mixture we could isolate 
a cycloheptatriene derivative (4) in 8% yield. Besides 4 a side-
product with an open d ring (5) could also be detected.
The formation of compound 4 occurs with insertion of a 
methylene group into the aromatic ring. The reaction is known 
in the literature and was mainly investigated in relatively sim-
ple aromatics to prepare tropylium salts with different substit-
uents [33-36]. (The formation of compound 5 can be explained 
with an oxidative ring opening of 1; N-formylation reaction 
with diazomethane is known in the literature [37].)
According to the literature [33] the Rh/C catalyst gives 
the best yields in these types of reaction and in some cases 
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copper(I) halogenides, copper(I) chloride [34] and copper(I) 
bromide [35,36] were also effective. Using Rh/C catalyst no 
reaction was observed between 1 and diazomethane. Per-
forming the reaction in the presence of copper(I) bromide, 
however, the cycloheptatriene derivative 4 was isolated in 
13% yield. Replacing diazomethane with trimethylsilyldi-
azomethane [38] proved to be unsuccessful.
Based on literature results [39] a possible mechanism is pre-
sented in Scheme 2. Carbene formed from diazomethane attach-
es to the aromatic a ring (1a) producing the cycloheptatriene 
derivative (4) via a norcaradiene-type intermediate (1b).
Formation of an aromatic methyl derivative (1c) in this reac-
tion is also possible, but no traces of this product were detected.
In summary, an attempted cyclopropanation of the carbon-
carbon double bond in the c ring of galanthamine (1) with di-
azomethane resulted in a new derivative (4) with a cyclohep-
tatriene structure in place of the aromatic a ring. Such a reac-
tion with methylene insertion into an aromatic ring has not yet 
been described in the field of natural compounds.
2.2 Synthesis and in vitro antitumor effect of new 
vindoline derivatives coupled with amino acid esters [40]
The dimeric alkaloids vinblastine (6) and vincristine (7) 
(Scheme 3) were isolated from the Madagascar periwinkle Ca-
tharanthus roseus. Both materials have been used in anticancer 
chemotherapy for more than forty years [41,42]. Vinblastine (6) 
is an antimicrotubule drug used to treat certain kinds of cancer, 
including Hodgkin’s lymphoma, non-small cell lung cancer, 
breast cancer, head and neck cancer, and testicular cancer. Vin-
cristine (7), the formyl derivative of vinblastine, can be used in 
various types of chemotherapy regimens. Its main uses are in 
non-Hodgkin’s and Hodgkin’s lymphoma, acute lymphoblastic 
leukemia, and in the treatment of nephroblastoma (Wilms tu-
mor, a kidney tumor most common in young children). These 
dimeric alkaloids have two monomer alkaloid parts: vindoline 
(8) and catharanthine (9) (Scheme 3). Although the chemis-
try and pharmacology of vinblastine and vincristine are well 
known, and a number of their derivatives were synthesized to 
improve their therapeutic properties [43], however, vindoline 
and its derivatives were found to be biologically insignificant, 
Scheme 2
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therefore there is much fewer data on their chemistry and bio-
logical effect in the literature [44].
Our research project was conceived on the basis of two in-
teresting experiences in connection with dimeric alkaloids.
Firstly, some amino acid derivatives of vinblastine and vin-
cristine were synthesized by coupling amino acid esters with 
the vindoline part in position 16 [45]. The obtained conjugates 
exhibited significant antitumor effect against P388 and L1210 
leukemia in mice. At the same time (D)- and (L)-tryptophan 
derivatives at the 16-position of desacetylvinblastine were 
conjugated through the carboxyl group with oligoarginine oc-
tapeptide as a carrier peptide at the N-terminus by Bánóczi et 
al. [46] One of the obtained stereoisomers showed a selective 
cytotoxic effect against the HL-60 human leukemia cells of 
higher proliferation rate.
Secondly, for dihydrovinblastine (i.e. vinblastine saturated 
in the 14,15-position of the vindoline part) a decreased anti-
tumor activity and toxicity was observed, probably due to a 
different mechanism of action from vinblastine [47]. These 
observations suggest that amino acid conjugation and reduc-
tion of the 14,15-position both alter the mechanism of action. 
Based on these observations our goal was to couple vindoline 
(8), 14,15-dihydrovindoline, and vindoline condensed with a 
cyclopropane ring in position 14,15, with (L)- and (D)-tryp-
tophan methyl ester at position 16 with a view to screening 
their biological effect. The azide coupling method known from 
peptide chemistry was used as the key step in the coupling of 
vindoline with the amino group of the amino acid ester.
The first task was to protect position 10 of vindoline, because 
in the presence of sodium nitrite used in the preparation of the 
corresponding azide, a nitrosation reaction took place in posi-
tion 10, resulting in 10-nitrosovindoline [44]. In this procedure 
a bromo substituent was used to protect position 10 (Scheme 4).
10-Bromovindoline (10) was prepared by us from vindoline 
(8) in a simple bromination reaction using N-bromosuccinimide 
[44]. 14,15-Dihydrovindoline (11) is known from the literature 
[48], and was obtained by catalytic hydrogenation of vindoline 
(8). Analogously with the previous reaction, bromination of the 
saturated derivative 11 resulted in 10-bromo-14,15-dihydrovindo-
line (12). The cyclopropane ring was built into position 14,15 by 
a typical Simmons-Smith reaction from 10-bromovindoline (10) 
using diethylzinc and diiodomethane, yielding compound 13.
Hydrazides of 10-bromovindoline (14a), 14,15-dihydrovin-
doline (14b), and 14,15-cyclopropanovindoline (14c), were 
synthesized from the corresponding bromo esters 10-bromovin-
doline (10), 10-bromo-14,15-dihydrovindoline (12), and 10-bro-
mo-14,15-cyclopropanovindoline (13), respectively, with hy-
drazine hydrate (Scheme 5). Hydrazine, as a strong nucleophile, 
caused desacetylation in position 17 during the reaction, and so 
the 17-desacetylated hydrazides were obtained as products.
Coupling the vindoline derivatives with tryptophan methyl 
esters was achieved by preparation of the azides (Scheme 6). 
The reaction of hydrazide 14a with sodium nitrite in metha-
nol in the presence of hydrochloric acid resulted in azide 15a, 
which was then allowed to react without isolation with (L)-
tryptophan methyl ester to yield the vindoline conjugate 16a.
Scheme 3
 
 
7Cyclopropanation of Some Alkaloids 2015 59 1
Scheme 5
Scheme 4
 
 
 
 
8 Per. Pol. Chem. Eng. Péter KEGLEVICH, László HAZAI, György KALAUS, Csaba SZÁNTAY
Using this procedure 14,15-dihydrovindoline and 14,15-cy-
clopropano vindoline were also coupled with (L)-tryptophan me-
thyl ester, yielding compounds 16e and 16i, respectively.
The derivatives containing (D)-tryptophan methyl ester (16c, 
16g, 16k) were synthesized analogously. In the case of com-
pounds 16a, 16c, 16e, 16g, 16i and 16k, the bromo substituent 
was removed from position 10 by hydrogenolysis to give com-
pounds 16b, 16d, 16f, 16h, 16j and 16l, respectively.
The influence of the different modifications of the ring sys-
tem and/or the conjugation with tryptophan on the in vitro cy-
tostasis of HL-60 human leukemia cells was analysed by using 
MTT assay [49] (Table 1).
2.3 Vinblastine and vincristine condensed
with a cyclopropane ring [50]
In the course of the synthetic investigations of dimeric Vin-
ca alkaloids various methods have been elaborated to synthe-
size new derivatives of vinblastine (6) and vincristine (7) with 
improved therapeutic effect exhibiting higher selectivity and 
lower toxicity [43,51].
One of the structural modifications was very simple and 
only a little part of the large molecule was changed; 14,15-di-
hydrovinblastine (17) having a saturated vindoline ring was 
simply prepared by catalytic hydrogenation of vinblastine (6) 
(Scheme 7), and the antitumor activity almost ceased [47].
The introduction of a cyclopropane ring in place of the 
C(14)=C(15) carbon carbon double bond of the vindoline ring 
(18) can be regarded as a minor change within the overall 
molecular framework of vinblastine; however, the electronic 
nature of this small ring has entirely special properties. Ac-
cording to NMR and X-ray-crystallographyc studies, the elec-
tronic structure of the cyclopropane ring cannot be described 
in terms of classical methods [22,23].
Our enquiry was aimed at finding out how the introduc-
tion of this unique structural system into vinblastine and vin-
cristine will influence their biological effects. To that end we 
Scheme 6
 
 
9Cyclopropanation of Some Alkaloids 2015 59 1
Table 1 Cytostatic activity of vindoline derivatives on HL-60 cells.
Compound Code IC50 (µM)±s.d.
Methyl-{N-[10-bromo-17-O-desacetyl-16-des(methoxycarbonyl)--vindoline-16-carbonyl]-l-Trp} 16a 56.8±9.8
Methyl-{N-[10-bromo-17-O-desacetyl-16-des(methoxycarbonyl)--vindoline-16-carbonyl]-D-Trp} 16c 73.8±10.4
Methyl-{N-[17-O-desacetyl-16-des(methoxycarbonyl)--vindoline-16-carbonyl]-l-Trp} 16b 54.3±6.7
Methyl-{N-[17-O-desacetyl-16-des(methoxycarbonyl)--vindoline-16-carbonyl]-D-Trp} 16d 73.0±2.3
Methyl-{N-[10-bromo-14,15-dihydro-17-O-desacetyl-16--des(methoxycarbonyl)vindoline-16-carbonyl]-l-Trp} 16e 60.1±15.0
Methyl-{N-[14,15-dihydro-17-O-desacetyl-16-des(methoxycarbonyl)--vindoline-16-carbonyl]-l-Trp} 16f 27.5±1.5
Methyl-{N-[10-bromo-14,15-dihydro-17-O-desacetyl-16--des(methoxycarbonyl)vindoline-16-carbonyl]-D-Trp} 16g 60.8±1.3
Methyl-{N-[14,15-dihydro-17-O-desacetyl-16-des(methoxycarbonyl)vindoline-16-carbonyl]-D-tryptophanate} 16h 78.4±9.7
Methyl-{N-[10-bromo-14(S),15(R)-cyclopropano-17-O-desacetyl--16-des(methoxycarbonyl)vindoline-16-carbonyl]-l-Trp} 16i 75.3±2.3
Methyl-{N-[10-bromo-14(S),15(R)-cyclopropano-17-O-desacetyl--16-des(methoxycarbonyl)vindoline-16-carbonyl]-D-Trp} 16k 72.6±4.0
Methyl-{N-[14(S),15(R)-cyclopropano-17-O-desacetyl-16--des(methoxycarbonyl)vindoline-16-carbonyl]-l-Trp} 16j 77.1±8.1
Methyl-{N-[14(S),15(R)-cyclopropano-17-O-desacetyl-16--des(methoxycarbonyl)vindoline-16-carbonyl]-D-Trp} 16l >100
Vindoline 8 >100
set out to synthesize 14,15-cyclopropanovinblastine (18) and 
some derivatives thoseof.
A number of cyclopropanation reactions are known in the 
literature [28] such as the Simmon-Smith reaction [29,30] and 
its variants, e.g. that involving triisobutylaluminium [52] or di-
azomethane in the presence of a catalyst [32].
First we attempted the direct cyclopropanation of vinblas-
tine (VBL) (6) and vincristine (VCR) (7). In the course of the 
reaction of vinblastine (6) using diiodomethane in the presence 
of diethylzinc in dichloromethane solution no cyclopropana-
tion occurred; a quaternary salt (19) was isolated in 18% yield 
and two rearranged products were found in a 2:1 mixture by 
NMR spectroscopy, vinamidine [53-56] (21) and cyclovinblas-
tine [58] (23) (Scheme 8). The latter are known in the literature 
and were identified by NMR.
Similarly, when treating vincristine (7) under such reac-
tion conditions the corresponding 20 quaternary salt was 
isolated in 9% yield, and N-formylcatharinine [57] (22) and 
Scheme 7
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cyclovincristine [58] (24) were identified by NMR spectros-
copy as a 1:1 mixture. Using the triisobutylaluminium method 
[52], only decomposed products were obtained from the reac-
tion mixtures.
Therefore the coupling reaction traditionally used to obtain 
dimeric alkaloids was selected to synthesize the expected cy-
clopropanated derivatives.
As the result of the reaction of vindoline (8) with diio-
domethane in the presence of diethylzinc in dichloromethane 
solution, only the cyclopropanated dimer (25) could be isolated 
(Scheme 9) with 6% yield. 
The 14,15-cyclopropano derivative of 10-bromovindoline 
(26) was previously prepared by us [40] from 10-bromovin-
doline [44] (10) in the reaction with diiodomethane and with 
diethylzinc in dichloromethane (Scheme 9). 10-Bromo-14,15-
cyclopropanovindoline (26) was treated in methanol with so-
dium borohydride in the presence of palladium on charcoal, 
which resulted in the expected 14,15-cyclopropanovindoline 
(27) unsubstituted in position 10.
Compound 27 proved to be suitable for the coupling reac-
tion with catharanthine to give cyclopropano-vinblastine and 
cyclopropano-vincristine.
The next step in our synthetic work was to prepare the cyclo-
propanated anhydrovinblastine (28), which can be an important 
intermediate in the synthesis of further derivatives (Scheme 10). 
14,15-Cyclopropanovindoline was coupled with catharanthine 
(9) by the method of biomimetic iron(III)-promoted coupling 
reaction [59,60]. The procedure used by us is the traditional 
coupling reaction for the preparation of dimeric alkaloids.
Catharanthine (9) and 14,15-cyclopropanovindoline (27) 
were dissolved in diluted aqueous hydrochloric acid solution 
together with the non-nucleophilic cosolvent 2,2,2-trifluoro-
ethanol (Scheme 10). The reaction was carried out at room 
temperature. Sodium borohydride was used as the reducing 
agent in water at 0 oC. 14,15-Cyclopropanoanhydrovinblastine 
(28) was obtained in 51% yield and was isolated by preparative 
thin-layer chromatography. From 28 base the sulfate salt was 
prepared immediately.
Hydration of the obtained anhydrovinblastine derivative 
(28) to 14,15-propanovinblastine (29) was carried out by the 
known oxidation protocol [69,60] utilizing the oxalate salt 
Fe2(ox)3 and air at 0 oC in water, diluted aqueous hydrochloric 
acid and 2,2,2-trifluoroethanol mixture. After purification the 
crude product with preparative thin-layer chromatography was 
transformed into the sulfate salt. 14,15-Cyclopropanovinblas-
tine (29) was obtained in 13% yield.
The new cyclopropano derivative of vinblastine (29) 
was oxidized [61] to 14,15-cyclopropanovincristine (30) by 
chromium(VI)oxide in acetone-acetic acid solution in the pres-
ence of acetic anhydride at -60 oC. The crude product which 
contained some N-demethylvincristine was reformylated with 
formic acid/acetic anhydride. After isolation the product by 
Scheme 8
 
 
11Cyclopropanation of Some Alkaloids 2015 59 1
Scheme 9
Scheme 10
 
 
 
 
preparative thin-layer chromatography, sulfate salt was pre-
pared and the expected product (30) was obtained in 52% yield.
The new compounds synthesized by us were sent to the US 
National Institute of Health (NIH) where they were subjected to 
pharmacological investigations. These experiments on 56 differ-
ent tumor cell lines embracing 9 frequently occurring tumor types 
demonstrated the therapeutic activity of these substances in com-
parison with other known effective catharanthus alkaloids.
Tumor types and cell lines were the following: leukemia 
(CCRF-CEM, HL(60)-TB, K-562, MOLT-4, RPMI-8226, SR), 
non-small cell lung cancer (A549/ATCC, EKVX, HOP-62, 
HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI-
H522), colon cancer (COLO 205, HCC-2998, HCT-116, HCT-
15, HT-29, KM12, SW-620), CNS cancer (SF-268, SF-295, 
SF-539, SNB-19, SNB-75, U251), melanoma (LOX IMVI, 
MALME-3M, M14, MDA-MB-435, SK-MEL-2, SK-MEL-28, 
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SK-MEL-5, UACC-257, UACC-62), ovarian cancer (IG-
ROV1, OVCAR-3, OVCAR-4, OVCAR-8, NCI/ADR-RES, 
SK-OV-3), renal cancer (786-0, A498, ACHN, CAKI-1, RXF 
393, SN12C, TK-10, UO-31), prostate cancer (PC-3, DU-145), 
breast cancer (MCF7, MDA-MB-231/ATCC, HS 578T, BT-
498, T-47D, MDA-MB-468).
The NCI screening procedures were described [62] as were 
the origins and processing of the cell lines [62-64]. In Table 2 
percentages of growths are listed for the reference alkaloids 
and the appropriate cyclopropano derivatives at the concentra-
tion of 10-5M. The bigger negative numbers show more signifi-
cant decrease of cell number or stronger inhibition effects.
According to Table 2 cyclopropano-vinblastine (29) has sig-
nificant tumor cell inhibiting effect in leukemia, non-small-cell 
lung cancer, colon cancer, melanoma and breast cancer, cyclopro-
pano-vincristine (30) has significant tumor cell inhibiting effect 
in colon cancer, melanoma, ovarian cancer and prostate cancer.
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